<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03311503</url>
  </required_header>
  <id_info>
    <org_study_id>P00023098</org_study_id>
    <nct_id>NCT03311503</nct_id>
  </id_info>
  <brief_title>Phase I/II Trial of Lentiviral Gene Transfer for SCID-X1 With Low Dose Targeted Busulfan Conditioning</brief_title>
  <official_title>Phase I/II Trial of Lentiviral Gene Transfer for SCID-X1 With Low Dose Targeted Busulfan Conditioning</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>David Williams</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Boston Children's Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a phase I/II open label multi-center study in which patients will receive low dose&#xD;
      targeted busulfan followed by infusion of autologous CD34+ selected bone marrow or mobilized&#xD;
      peripheral blood cells transduced with the G2SCID vector. Subjects will be enrolled over 3&#xD;
      years and be followed for 2 years post-infusion on this protocol, then followed long-term on&#xD;
      a separate long-term follow-up protocol.&#xD;
&#xD;
      Enrollment of subjects will be agreed upon by representatives of both sites. Data will be&#xD;
      collected uniformly from both sites through an electronic capture system and key laboratory&#xD;
      studies will be centralized.&#xD;
&#xD;
      Harvest, cellular manufacturing and infusion will occur at each site using the same SOPs. Key&#xD;
      aspects of cellular product characterization will be centralized&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is an open labeled, multi-center, phase I/II, cohort study involving a single infusion&#xD;
      of autologous CD34+ cells transduced with the self-inactivating (SIN) lentiviral vector&#xD;
      G2SCID in up to 10 patients with X-linked SCID (SCID-X1) at Boston Children's Hospital and&#xD;
      UCLA Mattel Children's Hospital. Patients will receive transduced cells after low dose&#xD;
      targeted busulfan pre-conditioning (n=10).&#xD;
&#xD;
      Enrolled subjects will be followed for 2 years after infusion on this protocol. Required&#xD;
      long-term monitoring for a total of 15 years after infusion will be performed on a separate&#xD;
      protocol.&#xD;
&#xD;
      Single infusion of autologous CD34+ cells transduced with the SIN lentiviral vector&#xD;
      rHIV_IL2RGcoG2SCID (hereafter G2SCID) The primary objective is to measure event free survival&#xD;
      and T cell immune reconstitution at 1 year post-infusion&#xD;
&#xD;
      Secondary objectives are to measure overall survival, event-free survival, safety related to&#xD;
      the procedure, and clinical and laboratory measures of efficacy including humoral immune&#xD;
      reconstitution and gene marking after gene transfer.&#xD;
&#xD;
      Exploratory objectives include: molecular characterization of gene transfer, detailed&#xD;
      assessment of biomarkers of T and B cell development and function, assessment of infections,&#xD;
      nutritional status, growth and development post gene therapy, assessment of T cell receptor&#xD;
      and B cell receptor repertoire by next generation sequencing, correlation of busulfan levels&#xD;
      with immune outcome and molecular measurements of gene transfer&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">January 19, 2018</start_date>
  <completion_date type="Anticipated">January 1, 2024</completion_date>
  <primary_completion_date type="Anticipated">January 1, 2022</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <intervention_model_description>open labeled, multi-center, phase I/II, cohort study</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The primary objective is to measure event free survival</measure>
    <time_frame>1 year post infusion</time_frame>
    <description>Events will include death, infusion of unmanipulated back-up product for failure of hematopoietic recovery, and allogeneic transplant performed for poor immune reconstitution</description>
  </primary_outcome>
  <primary_outcome>
    <measure>T cell reconstitution</measure>
    <time_frame>1 year post infusion</time_frame>
    <description>CD3+ T cell count ≥300 cells/microliter in peripheral blood&#xD;
Gene marking ≥0.1 copies/cell in sorted CD3+ T cells</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">10</enrollment>
  <condition>Severe Combined Immunodeficiency, X Linked</condition>
  <condition>Gene Therapy</condition>
  <arm_group>
    <arm_group_label>Treatment arm</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>single infusion of autologous CD34+ cells transduced with the self-inactivating (SIN) lentiviral vector G2SCID</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>autologous CD34+ cell transduced with G2SCID vector</intervention_name>
    <description>single infusion of autologous CD34+ cells transduced with the self-inactivating (SIN) lentiviral vector G2SCID</description>
    <arm_group_label>Treatment arm</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        - 1. Diagnosis of SCID-X1 based on immunophenotype and lack of T cell function&#xD;
        (proliferation to PHA &lt;10% of the lower limit of normal for the laboratory) AND confirmed&#xD;
        by a mutation in IL2RG 2. Lack of an HLA identical (A, B, C, DR, DQ) related donor 3. Age 5&#xD;
        years old or younger 4. Signed informed consent 5. Documentation of willingness to follow&#xD;
        up for 15 years post-infusion as currently required by the FDA 6. If the patient has&#xD;
        previously undergone allogeneic transplant, lack of donor T cell engraftment must be&#xD;
        documented.&#xD;
&#xD;
        7. Age at least 8 weeks by the time of busulfan administration&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Patients with an active, therapy-resistant infection. Infections that are known to be&#xD;
             highly morbid in SCID patients will be considered active and therapy-resistant if the&#xD;
             infectious agent is repeatedly isolated despite a minimum of 2 weeks of appropriate&#xD;
             therapy and is associated with significant organ dysfunction (including but not&#xD;
             limited to abnormalities listed below).&#xD;
&#xD;
               1. Mechanical ventilation including continuous positive airway pressure&#xD;
&#xD;
               2. Abnormal liver function defined by AST and ALT &gt;10 times the upper range of&#xD;
                  normal OR Bilirubin &gt;2 mg/dL&#xD;
&#xD;
               3. Shortening fraction on echocardiogram &lt;25% or ejection fraction &lt;50%&#xD;
&#xD;
               4. Renal failure defined as glomerular filtration rate &lt;30 ml/min/1.73 m2 or&#xD;
                  dialysis dependence&#xD;
&#xD;
          2. Uncontrolled seizure disorder&#xD;
&#xD;
          3. Encephalopathy&#xD;
&#xD;
          4. Documented coexistence of any disorder known to affect DNA repair&#xD;
&#xD;
          5. Diagnosis of active malignant disease other than EBV-associated lymphoproliferative&#xD;
             disease&#xD;
&#xD;
          6. Patients with evidence of infection with HIV-1&#xD;
&#xD;
          7. Major (life-threatening) congenital anomalies. Examples of &quot;major (life-threatening)&#xD;
             congenital anomalies&quot; include, but are not limited to: unrepaired cyanotic heart&#xD;
             disease, hypoplastic lungs, anencephaly or other major central nervous system&#xD;
             malformations, other severe non-repairable malformations of the gastrointestinal or&#xD;
             genitourinary tracts that significantly impair organ function.&#xD;
&#xD;
          8. Other conditions which in the opinion of the P.I. or co-investigators, contra-indicate&#xD;
             collection and/or infusion of transduced cells or indicate patient's inability to&#xD;
             follow the protocol. These may include for example clinical ineligibility to receive&#xD;
             anesthesia, severe deterioriation of clinical condition of the patient after&#xD;
             collection of bone marrow but before infusion of transduced cells, or documented&#xD;
             refusal or inability of the family to return for scheduled visits. There may be other&#xD;
             unforeseen rare circumstances that would result in exclusion of the patient, such as&#xD;
             sudden loss of legal guardianship&#xD;
&#xD;
             -&#xD;
      </textblock>
    </criteria>
    <gender>Male</gender>
    <gender_based>Yes</gender_based>
    <gender_description>X linked</gender_description>
    <minimum_age>N/A</minimum_age>
    <maximum_age>5 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Sung-Yun Pai, MD</last_name>
    <role>Study Chair</role>
    <affiliation>National Institutes of Health (NIH)</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Colleen Dansereau</last_name>
    <phone>6179197008</phone>
    <email>colleen.dansereau@childrens.harvard.edu</email>
  </overall_contact>
  <location>
    <facility>
      <name>Mattel Children's Hospital - UCLA</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90095</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Donald Kohn, MD</last_name>
      <phone>310-825-6708</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Emory University/Childrens Healthcare of Atlanta</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30322</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Shanmuganathan Chandrakasan, MD</last_name>
      <phone>404-727-8877</phone>
      <email>Shanmuganathan.Chandrakasan@emory.edu</email>
    </contact>
    <investigator>
      <last_name>Shanmuganathan Chandrakasan, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Boston Childrens Hospital</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02115</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jennifer Whangbo, MD</last_name>
      <phone>617-632-2664</phone>
      <email>jennifer.whangbo@childrens.harvard.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Cincinnati Children's Hospital Medical Center</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <zip>45229</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sharat Chandra, M.D.</last_name>
      <phone>513-636-4266</phone>
      <email>Sharat.Chandra@cchmc.org</email>
    </contact>
    <investigator>
      <last_name>Sharat Chandra, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Great Ormond Street Hospital</name>
      <address>
        <city>London</city>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Claire Booth, MD</last_name>
      <email>c.booth@ucl.ac.uk</email>
    </contact>
    <investigator>
      <last_name>Claire Booth, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Adrian Thrasher, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United Kingdom</country>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2021</verification_date>
  <study_first_submitted>October 12, 2017</study_first_submitted>
  <study_first_submitted_qc>October 12, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">October 17, 2017</study_first_posted>
  <last_update_submitted>April 15, 2021</last_update_submitted>
  <last_update_submitted_qc>April 15, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">April 19, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Boston Children's Hospital</investigator_affiliation>
    <investigator_full_name>David Williams</investigator_full_name>
    <investigator_title>Chief Scientific Officer</investigator_title>
  </responsible_party>
  <keyword>lentiviral</keyword>
  <keyword>Gene therapy</keyword>
  <keyword>busulfan</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Severe Combined Immunodeficiency</mesh_term>
    <mesh_term>X-Linked Combined Immunodeficiency Diseases</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

